keyword
MENU ▼
Read by QxMD icon Read
search

hyperthermic intraperitoneal chemotherapy

keyword
https://www.readbyqxmd.com/read/29431036/outcomes-of-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-mesothelioma-and-predictors-of-survival
#1
Syeda Nadia Shah Gilani, Akash Mehta, Alfonso Garcia-Fadrique, Babatunde Rowaiye, Veronika Jenei, Sanjeev Dayal, Kandiah Chandrakumaran, Norman Carr, Faheez Mohamed, Tom Cecil, Brendan Moran
BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) benefits selected patients with peritoneal mesothelioma. We present the outcomes of this treatment strategy in a UK peritoneal malignancy national referral centre. METHODS: Observational retrospective analysis of data prospectively collected in a dedicated peritoneal malignancy database between March 1998 and January 2016. RESULTS: Of 1586 patients treated for peritoneal malignancy, 76 (4...
February 12, 2018: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/29429947/hospital-readmission-rates-and-risk-factors-for-readmission-following-cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec-for-peritoneal-surface-malignancies
#2
Yael Dreznik, Aviad Hoffman, Tamar Hamburger, Almog Ben-Yaacov, Yossi Dux, Harel Jacoby, Yaniv Berger, Aviram Nissan, Mordechai Gutman
BACKGROUND: Cytoreductive surgery and Hyperthermic intra-peritoneal chemotherapy (CRS/HIPEC) for peritoneal surface malignancies is associated with high morbidity. The increased numbers of patients undergoing CRS/HIPEC in recent years mandates risk analysis and quality assurance. However, only scarce data exist regarding causative parameters for readmission. The aim of this study was to assess readmission rates and risk factors associated with readmission. METHODS: A retrospective-cohort study including patients from two high-volume centers who underwent CRS/HIPEC surgery between the years 2007-2016 was performed...
February 8, 2018: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/29429054/incidence-of-leukopenia-and-thrombocytopenia-with-cisplatin-plus-mitomycin-c-versus-melphalan-in-patients-undergoing-cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec
#3
Hakeam A Hakeam, Amal Arab, Ayman Azzam, Zyad Alyahya, Abdelmoneim M Eldali, Tarek Amin
INTRODUCTION: Cytopenia after hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) has been reported in non-comparative studies with various chemotherapeutic regimens. This study compared the incidence of leukopenia and thrombocytopenia in patients who underwent CRS/HIPEC and received melphalan or cisplatin plus mitomycin-c (CIS + MMC). METHODS: This retrospective study included patients who underwent CRS/HIPEC at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia from March 2011 to March 2017 and received melphalan 60 mg/m2 or CIS 100 mg/m2 combined with MMC 30 mg/m2...
February 10, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29428475/peritoneal-metastases-invading-the-seminal-vesicles-radiologic-appearance-and-outcome-of-treatment
#4
Paul H Sugarbaker
BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may be of greatest benefit if all visible evidence of disease is resected. In some male patients the peritoneal metastases within the pelvis are invasive into the seminal vesicles and complete cytoreduction requires resection of these structures. PATIENTS AND METHODS: From a prospective database of colorectal and appendiceal cancer patients who had CT evidence of seminal vesicle involvement and then had cytoreduction including resection of the seminal vesicles were reviewed...
January 12, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29423664/current-management-and-future-opportunities-for-peritoneal-metastases-peritoneal-mesothelioma
#5
H Richard Alexander, Claire Yue Li, Timothy J Kennedy
PURPOSE: Diffuse malignant peritoneal mesothelioma (MPM) is a rare and ultimately fatal cancer that was first described just over a century ago. It is a diffuse malignancy arising from the mesothelial lining of the peritoneum; morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. METHODS: The purpose of this article is to review the current state-of-the-science related to the diagnosis, staging, and treatment of MPM...
February 8, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29414017/a-validated-inductively-coupled-plasma-mass-spectrometry-icp-ms-method-for-the-quantification-of-total-platinum-content-in-plasma-plasma-ultrafiltrate-urine-and-peritoneal-fluid
#6
Lieselotte Lemoine, Elsy Thijssen, Jean-Paul Noben, Peter Adriaensens, Robert Carleer, Kurt Van der Speeten
Oxaliplatin is a platinum (Pt)1 containing antineoplastic agent that is applied in current clinical practice for the treatment of colon and appendiceal neoplasms. A fully validated, highly sensitive, high throughput inductively coupled plasma mass spectrometry (ICP-MS) method is provided to quantify the total Pt content in plasma, plasma ultrafiltrate, urine and peritoneal fluid. In this ICP-MS approach, the only step of sample preparation is a 1000-fold dilution in 0.5% nitric acid, allowing the analysis of 17 samples per hour...
January 29, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29412465/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-pseudomyxoma-peritonei-of-appendicular-and-extra-appendicular-origin
#7
J-B Delhorme, F Severac, G Averous, O Glehen, G Passot, N Bakrin, F Marchal, M Pocard, R Lo Dico, C Eveno, S Carrere, O Sgarbura, F Quenet, G Ferron, D Goéré, C Brigand
BACKGROUND: The prognostic value of the primary neoplasm responsible for pseudomyxoma peritonei (PMP) remains poorly studied. The aim of this study was to determine the prognosis for patients with extra-appendicular PMP (EA-PMP) treated optimally with complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: All patients treated for PMP with CCRS and HIPEC between 1994 and 2016 were selected retrospectively from a French multicentre database...
February 7, 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29397879/systematic-second-look-surgery-plus-hipec-in-patients-without-evidence-of-recurrence-at-high-risk-of-carcinomatosis-after-colorectal-cancer-resection
#8
Ángel Serrano Del Moral, Estibalitz Pérez Viejo, Israel Manzanedo Romero, Gil Rodríguez Caravaca, Fernando Pereira Pérez
INTRODUCTION: To analyze the impact of systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) performed 1 year after resection of the primary tumor, in asymptomatic patients at high risk of developing peritoneal carcinomatosis (PC). METHODS: Between 2012-2016, 33 patients without any sign of peritoneal recurrence on imaging studies were prospectively included in the study and underwent second-look surgery aimed at treating limited PC earlier and were prospectively recorded...
February 2, 2018: Cirugía Española
https://www.readbyqxmd.com/read/29397633/analysis-of-patient-selection-policy-and-pattern-of-recurrence-after-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-colorectal-carcinomatosis
#9
Manuela Robella, Marco Vaira, Alice Borsano, Michele DE Simone
BACKGROUND: Actual cure rate and patterns of recurrence after cytoreductive surgery (CRS) associated to hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with colorectal peritoneal carcinomatosis (PC) are not yet well explored. Moreover, the selection policy to this resource-consuming treatment is still a matter of debate. METHODS: From a dataset of 400 CRS+HIPEC performed between October 1996 and December 2015, we selected 54 consecutive patients with colorectal PC...
February 1, 2018: Minerva Chirurgica
https://www.readbyqxmd.com/read/29388121/techniques-for-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy
#10
Rebecca M Dodson, Michael Kuncewitch, Konstantinos I Votanopoulos, Perry Shen, Edward A Levine
No abstract text is available yet for this article.
January 31, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29383611/desmoplastic-small-round-cell-tumor-treated-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-results-of-a-phase-2-trial
#11
Andrea A Hayes-Jordan, Brian A Coakley, Holly L Green, LianChun Xiao, Keith F Fournier, Cynthia E Herzog, Joseph A Ludwig, Mary F McAleer, Peter M Anderson, Winston W Huh
BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma that primarily affects adolescents and young adults. Patients can present with many peritoneal implants. We conducted a phase 2 clinical trial utilizing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) with cisplatin for DSRCT and pediatric-type abdominal sarcomas. PATIENTS AND METHODS: A prospective cohort study was performed on 20 patients, who underwent CRS-HIPEC procedures, with cisplatin from 2012 to 2013...
January 30, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29381126/the-evolving-management-of-small-bowel-adenocarcinoma
#12
Eelco de Bree, Koen P Rovers, Dimitris Stamatiou, John Souglakos, Dimosthenis Michelakis, Ignace H de Hingh
BACKGROUND: Small bowel adenocarcinoma (SBA) is rare despite the fact that the small bowel represents the longest part and has the largest surface of all alimentary tract sections. Its incidence is 50-fold lower than that of colorectal carcinoma. It is often diagnosed at an advanced stage due to atypical and late symptoms, its low index of suspicion, difficult endoscopic access and poor detection by radiological imaging, resulting in impaired outcome. Due to its rarity and being molecularly a unique intestinal cancer, data regarding its optimal management are relatively sparse...
January 30, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29374723/low-dose-pressurized-intrathoracic-aerosol-chemotherapy-pitac-as-an-alternative-therapy-for-pleuropulmonary-involvement-in-pseudomyxoma-peritonei
#13
Manuela Robella, Marco Vaira, Alice Borsano, Claudio Mossetti, Michele DE Simone
BACKGROUND/AIM: Pseudomyxoma peritonei (PMP) is a rare disease characterized by mucinous ascites and widespread peritoneal implants. It usually originates from the rupture of an adenoma/adenocarcinoma of the appendix. Although this tumor is only superficially invasive and does not metastasize, it could be a fatal disease. Extra-abdominal spread of PMP is an unusual occurrence with few reports in medical literature. CASE REPORT: A 50-year-old man was diagnosed with PMP according to the findings of thorax and abdomen CT scan and cytologic and histological examinations...
February 2018: Anticancer Research
https://www.readbyqxmd.com/read/29363016/cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec-a-single-center-experience-in-austria
#14
Kogler Pamela, Zitt Matthias, Kafka-Ritsch Reinhold, Punter Julia, Müssigang Peter, Perathoner Alexander, Öfner Dietmar
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly influence overall and disease-free survival in selected patients suffering from peritoneal surface malignancies (PSM) of various tumor entities. Because of the extent of the therapeutic approach, the associated morbidity and mortality and the multidisciplinarity needed, implementation of a CRS + HIPEC program at an institution is often challenging. METHODS: This single-center analysis included all patients (n = 60, 34 female, 26 male) with PSM from various tumor primaries [colorectal cancer (15/60; 25%), appendix neoplasia (21/60; 35%), and others (24/60; 40%)] treated with CRS + HIPEC at our institution between 2006 and 2014...
January 23, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29355970/comparison-of-open-and-closed-abdomen-techniques-for-the-delivery-of-intraperitoneal-pemetrexed-using-a-murine-model
#15
David Badrudin, Lucas Sideris, Camille Perrault-Mercier, Julien Hubert, François A Leblond, Pierre Dubé
BACKGROUND AND OBJECTIVES: Pemetrexed is an appealing agent to use for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the optimal method of pemetrexed delivery still remains undefined. Using a murine model, we compared the use of open and closed abdomen techniques on the absorption of intraperitoneal (IP) pemetrexed in different compartments. METHODS: Eleven Sprague-Dawley rats were submitted to a fixed dose of IP pemetrexed (1000 mg/m2 ) at a perfusion temperature of 40°C during 25 min according to two techniques: open and closed...
January 22, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29342393/hyperthermic-intraperitoneal-chemotherapy-in-ovarian-cancer
#16
RANDOMIZED CONTROLLED TRIAL
Willemien J van Driel, Simone N Koole, Karolina Sikorska, Jules H Schagen van Leeuwen, Henk W R Schreuder, Ralph H M Hermans, Ignace H J T de Hingh, Jacobus van der Velden, Henriëtte J Arts, Leon F A G Massuger, Arend G J Aalbers, Victor J Verwaal, Jacobien M Kieffer, Koen K Van de Vijver, Harm van Tinteren, Neil K Aaronson, Gabe S Sonke
BACKGROUND: Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer. METHODS: In a multicenter, open-label, phase 3 trial, we randomly assigned 245 patients who had at least stable disease after three cycles of carboplatin (area under the curve of 5 to 6 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area) to undergo interval cytoreductive surgery either with or without administration of HIPEC with cisplatin (100 mg per square meter)...
January 18, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29341165/histopathological-and-molecular-classification-of-colorectal-cancer-and-corresponding-peritoneal-metastases
#17
I Ubink, W J van Eden, P Snaebjornsson, N F M Kok, J van Kuik, W M U van Grevenstein, M M Laclé, J Sanders, R J A Fijneman, S G Elias, I H M Borel Rinkes, A G J Aalbers, O Kranenburg
BACKGROUND: Patients with colorectal peritoneal carcinomatosis have a very poor prognosis. The recently developed consensus molecular subtype (CMS) classification of primary colorectal cancer categorizes tumours into four robust subtypes, which could guide subtype-targeted therapy. CMS4, also known as the mesenchymal subtype, has the greatest propensity to form distant metastases. CMS4 status and histopathological features of colorectal peritoneal carcinomatosis were investigated in this study...
January 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29335393/peritoneal-metastases-of-colorectal-origin-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-the-financial-aspect
#18
Tomasz Jastrzębski, Marek Bębenek
The incidence of peritoneal carcinomatosis of colorectal cancer amounts to 5%-15% for synchronous metastases and as much as 40% in cases of local recurrence. Best results are obtained for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). This treatment offers much better outcomes, leading to 5-year survival rates of as much as 30%-50%. The procedures require significant experience in abdominal surgery, are time-consuming (mean duration of the procedure ranging from 6 to 8 hours) and are burdened by complications that are due not only to the procedure itself but also to the intraperitoneal administration of the cytostatic drug at elevated temperature (41...
December 30, 2017: Polski Przeglad Chirurgiczny
https://www.readbyqxmd.com/read/29332351/cytoreductive-surgery-and-hyperthermic-intraperitenoal-chemotherapy-hipec-for-colorectal-and-appendiceal-carcinomas-with-peritoneal-carcinomatosis
#19
Nicolaos Pallas, Christina Karamveri, Dimitrios Kyziridis, Christos Hristakis, Vasileios Kyriakopoulos, Apostolos Kalakonas, Dimitrios Vaikos, Antonios-Apostolos K Tentes
PURPOSE: Cytoreductive surgery combined with intraperitoneal chemotherapy has been established as the standard treatment for selected patients with peritoneal malignancy. The purpose of the study was the presentation of the 10- year experience with cytoreductive surgery and intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal and appendiceal origin. METHODS: Clinical and histopathological variables were retrospectively reviewed in a prospectively maintained database...
November 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29331663/a-multi-center-randomized-trial-to-evaluate-hematologic-toxicities-after-hyperthermic-intraperitoneal-chemotherapy-with-oxaliplatin-or-mitomycin-in-patients-with-appendiceal-tumors
#20
Edward A Levine, Konstantinos I Votanopoulos, Perry Shen, Greg Russell, Joyce Fenstermaker, Paul Mansfield, David Bartlett, John H Stewart
BACKGROUND: Appendiceal cancer is a rare disease, which has proven difficult to study in prospective trials. Cytoreductive surgery with HIPEC is an established therapy for peritoneal dissemination from appendiceal cancer. The optimal chemotherapeutic agent to use in the HIPEC is not clear. Mitomycin has long been the utilized, however our previous phase I experience, and European retrospective studies suggest oxaliplatin as an alternative. Therefore, we initiated a multicenter randomized trial to compare mitomycin to oxaliplatin HIPEC for appendiceal cancer...
January 10, 2018: Journal of the American College of Surgeons
keyword
keyword
84002
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"